Homburger with Siegfried on drug substances sites acquisition

Homburger advised Siegfried Holding in connection with the bridge financing for the acquisition of three drug substances sites in the US and Australia.

The context

On May 1, 2026, Siegfried Holding, a globally active Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, closed the acquisition of three drug substances sites in the US and Australia from an affiliate of SK Capital Partners.

Homburger acted as counsel to Siegfried Holding in connection with a Swiss law-governed bridge term facility agreement with UBS Switzerland as mandated lead arranger and lender.

The Homburger team

Jürg Frick (financing, pictured) led the Homburger team on the matter, working alongside Stefan Bindschedler (financing) and Stefan Oesterhelt (tax).